Enliven Therapeutics, Inc.
ELVN
$36.87
$0.762.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.14M | 13.04M | 6.87M | 7.09M | 6.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.82M | 34.29M | 25.10M | 28.58M | 31.69M |
| Operating Income | -27.82M | -34.29M | -25.10M | -28.58M | -31.69M |
| Income Before Tax | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M |
| EBIT | -27.82M | -34.29M | -25.10M | -28.58M | -31.69M |
| EBITDA | -27.81M | -34.24M | -25.03M | -28.50M | -31.62M |
| EPS Basic | -0.38 | -0.48 | -0.32 | -0.49 | -0.57 |
| Normalized Basic EPS | -0.24 | -0.30 | -0.20 | -0.30 | -0.36 |
| EPS Diluted | -0.38 | -0.48 | -0.32 | -0.49 | -0.57 |
| Normalized Diluted EPS | -0.24 | -0.30 | -0.20 | -0.30 | -0.36 |
| Average Basic Shares Outstanding | 62.80M | 62.21M | 62.09M | 52.11M | 50.05M |
| Average Diluted Shares Outstanding | 62.80M | 62.21M | 62.09M | 52.11M | 50.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |